EmbryoScope+ approved for sales in China
Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in China, the world's largest market measured in terms of number of IVF treatments.EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. In 2018, Vitrolife received market approval in China for the EmbryoScope time-lapse system, with capacity for six patients. "We are delighted to receive market approval